# Synthyra Strategy Alignment Deck

## Narrative Framework
- Primary: Minto Pyramid with SCQA opener
- Metaphor family: Runway and gates

## Slides

### 1. Title
**Headline:** 6-9 months from fundable.
**Spotlight:** Compelling tech, thin evidence. Close five proof points to unlock a $12-18M raise.
**Design note:** Minimal title slide with five chips signaling proof points.
**Source:** [PARAPHRASE] resources/materials/executive_summary.md, resources/materials/strategy_analysis.md

### 2. Problem
**Headline:** Blind experimentation burns a decade before you know a drug fails.
**Spotlight:** 90% trial failure, $100M+ late-stage burn, 10+ year cycles.
**Design note:** Funnel visual showing 100 candidates to 1 approval.
**Source:** [GENERATED] (contextual stats for framing)

### 3. Infrastructure
**Headline:** Real-time proteome screening makes biology searchable.
**Spotlight:** 375M interactions/sec; full human proteome in under 2 seconds.
**Design note:** Dark theme with looping network visualization.
**Source:** [PARAPHRASE] resources/materials/strategy_analysis.md, resources/product-doc-x.md

### 4. Platform
**Headline:** Four engines convert sequence data into go/no-go decisions.
**Spotlight:** DSM, CAMP, Synteract Turbo, and Synteract 4 power the generate-annotate-screen-decide workflow.
**Design note:** Stack diagram with labeled engines and throughput callout.
**Source:** [PARAPHRASE] resources/product-doc-x.md

### 5. Go-to-Market
**Headline:** Safety and Toxicity is the fastest, clearest wedge.
**Spotlight:** Partnership-first pilots now, SaaS transition in 18-24 months.
**Design note:** Suite cards with Safety/Tox highlighted as recommended entry.
**Source:** [DIRECT] resources/materials/strategy_analysis.md

### 6. Verdict
**Headline:** Compelling tech, thin evidence, five proof points to close.
**Spotlight:** Panel verdict: 6-9 months from fundable if benchmarks, pilot, case study, SAB, and narrative land.
**Design note:** Left column framing cards for risk/opportunity; right column proof-point checklist.
**Source:** [DIRECT] resources/materials/strategy_analysis.md

### 7. Pricing
**Headline:** Hybrid reserve + usage aligns value without commoditizing.
**Spotlight:** $150K-350K pilot, 50% upfront; expansion at $500K-1.5M with success bonus optional.
**Design note:** Rate card table with non-negotiable deal terms underneath.
**Source:** [DIRECT] resources/materials/strategy_analysis.md, resources/materials/05_pricing_packaging_synthesis.md

### 8. Gaps
**Headline:** These are the investability gaps before we raise.
**Spotlight:** Benchmark, pilot, case study, SAB, narrative, pricing terms.
**Design note:** Six warning cards in a two-column grid.
**Source:** [PARAPHRASE] resources/materials/strategy_analysis.md

### 9. Initiatives
**Headline:** Initiatives map directly to the five proof points.
**Spotlight:** Benchmarks, case study, pilot, SAB, narrative deck, pricing architecture.
**Design note:** Initiative table with owners and timelines.
**Source:** [SYNTHESIZED] resources/materials/strategy_analysis.md, resources/materials/executive_summary.md

### 10. Raise
**Headline:** $12-18M buys 24 months and pharma credibility.
**Spotlight:** Series Seed positioning, $40-50M post, 9-12 month close window.
**Design note:** Raise metric cards plus use-of-funds bars.
**Source:** [DIRECT] resources/materials/strategy_analysis.md

### 11. Execution
**Headline:** Benchmark, pilot, then raise on a 6-9 month runway.
**Spotlight:** Month-by-month gates and this-week sprint by track.
**Design note:** Timeline steps with a three-track sprint panel.
**Source:** [PARAPHRASE] resources/materials/strategy_analysis.md
